News

Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera. Under a second agreement, Celera will receive royalties on the sale of

Approximately 230 patients were enrolled to this study, randomized into three groups treated with 0.1mg and 4mg of CF101, and placebo. Patients are taking the drug for 12

According to the company, the new high-capacity immunoassay system provides laboratories with a new system to address their quality, labor and cost challenges. The Vitros 3600 is expected

William Garner, CEO of Urigen Pharmaceuticals, said: “In co-operation with the University of California at San Diego (UCSD), we have amended the annual license payments to ensure that

Each share of Pediatrix will become a share of Mednax, and will trade on the New York Stock Exchange under the ticker symbol ‘MD’, when the US securities

The drug candidate is an antimicrobial peptide named Plectasin NZ2114 that targets the treatment of infections such as pneumonia and septicemia, caused by bacteria like Staphylococcus and Streptococcus.

In connection with the acquisition, Ligand issued approximately 18m shares of Ligand common stock to Pharmacopeia stockholders, or 0.60 shares for each outstanding Pharmacopeia share, as well as

Serbian oncology centers participating in the trial include the Clinical Hospital Center Benzanijska Kosa in Belgrade, the Clinic for Pulmonary Diseases and TB ‘Knez Selo’ in Nis, and

The clinical trial protocol has been reviewed by the FDA, and LifeCycle Pharma (LCP) expects to enroll approximately 300 stable kidney transplant patients in the program. The study